To amend title XVIII of the Social Security Act to provide a review process for adverse national coverage determinations with respect to drug coverage under the Medicare program.
Summary
HR 9418 is an early-stage bill introducing an administrative review process for Medicare Part B drug coverage determinations. It remains referred to two House committees with minimal progress. The impact on healthcare stocks is procedural and low-confidence: potential upside for drug manufacturers but negligible near-term revenue effects for major companies like JNJ, with a slight downside for managed care such as UNH through higher drug costs if coverage expands.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 9418 is procedural and early-stage, with no funding attached.
- 2.Unlikely to progress; needs committee hearings and cosponsor growth.
- 3.Negligible near-term profit impact for healthcare companies.
Market Implications
No immediate market signal. Early-stage legislation affecting a narrow administrative process within CMS has almost no detectable impact on healthcare equities. Drug manufacturers and managed care companies will not adjust guidance based on this bill. Retail investors should treat it as political noise and not reposition holdings.
Full Analysis
What happened: On June 24, 2026, Rep. Nanette Barragán (D-CA-44) introduced HR 9418, a bill to amend Title XVIII of the Social Security Act to establish a review process for adverse national coverage determinations (NCDs) regarding drug coverage under Medicare Part B. The bill was referred to the House Ways and Means Committee and the Energy and Commerce Committee. It has one cosponsor and is in an early legislative stage.
The money trail: No funding is authorized or appropriated by this bill. The mechanism is purely administrative—it mandates CMS to create a review process that manufacturers or beneficiaries can invoke to contest adverse NCDs. There is no direct budget line item; any costs would be absorbed by CMS operational budgets. Revenue impacts for drug companies would flow only indirectly, through specific future successful challenges, not from any allocation in this bill.
Convergence: No related candidate signals (procurement, presidential actions, or related bills) were provided with this bill. Therefore, no convergence analysis is performed. The bill stands alone as a procedural healthcare policy initiative.
Structural winners and losers: Drug manufacturers including JNJ, LLY, and others with significant Part B drug portfolios could see a slight improvement in regulatory risk profile, but the impact is marginal—NCDs are rare (about 10-15 per year). Managed care organizations like UNH and CVS (through Aetna) may face potential upward drug cost pressure, but again negligible in the near term. No clear sector-wide impact.
Timeline: With only a single sponsor and referral to two committees, passage in the 119th Congress is unlikely unless it gains co-sponsors and committee action. The bill has not seen a hearing, markup, or floor consideration. The earliest possible next steps would be a subcommittee hearing in late 2026 or 2027, but no scheduled activity is noted.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →